Healthy Clinical Trial
— BUCKFOODOfficial title:
Assessing the Effects of a Buckwheat Beverage on Postprandial Glucose Metabolism on Healthy and T2D Individuals
NCT number | NCT03923205 |
Other study ID # | 2-088-18 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 7, 2019 |
Est. completion date | March 31, 2021 |
Verified date | April 2019 |
Source | University of Aberdeen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Buckwheat is a unique crop because is naturally rich in compounds that have shown beneficial
effects on glucose metabolism.
A constant high glucose level in blood after meal consumption is an independent risk factor
for cardiovascular complications and death. In order to prevent Type 2 Diabetes Mellitus
(T2D) and/or its complications it is important to have a strict control of the blood glucose
levels after a meal. There are known therapies for the control of the high glucose blood
levels such as agents that act on intestinal digestion of carbohydrates and therapeutic
agents that mimic the insulin response after a meal. The combination of these type of agents
was commonly prescribed in the treatment of T2D.
The aim of the study is to assess the effect of a buckwheat beverage on postprandial glucose
metabolism in healthy individuals and those with T2D controlled by medication and diet.
Status | Recruiting |
Enrollment | 54 |
Est. completion date | March 31, 2021 |
Est. primary completion date | September 7, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Healthy and T2D (controlled by diet and lifestyle or metformin) volunteers; Age 18+; males and females. Exclusion Criteria: For the healthy group: - taking prescribed medication - HbA1c above 48mmol/mol (or 6.5%) - pregnant or breastfeeding - blood donation in the last three months - unable to give written informed consent - eating disorders such as anorexia, bulimia, binge eating or night eating syndrome. - significant health issue - taking vitamin or mineral supplements (unless they agree to discontinue supplementation 2 weeks or more before the start of the study) - Food allergies/intolerances For the T2D groups: - T2D controlled by medication other than metformin - pregnant or breastfeeding - blood donation in the last three months - unable to give written informed consent - eating disorders such as anorexia, bulimia, binge eating or night eating syndrome. - any other significant health issue other than T2D - taking vitamin or mineral supplements (unless they agree to discontinue supplementation 2 weeks before the start of the study) - food allergies/intolerances |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Rowett Institute, University of Aberdeen | Aberdeen |
Lead Sponsor | Collaborator |
---|---|
University of Aberdeen | NHS Grampian |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | post prandial blood glucose (recording cmax) | Postprandial blood glucose levels after acute consumption of a buckwheat beverage, recording the maximum blood glucose concentration (c max) over the baseline after the consumption of a buckwheat beverage. | five hours | |
Primary | AUC for postprandial glucose | Area under the curve described by the postprandial glucose level during five hours time | five hours | |
Secondary | post prandial blood insulin in blood ( including AUC) | Post prandial blood insulin levels after acute consumption of a buckwheat beverage. AUC (area under curve) for insulin for five hour interval. | five hours | |
Secondary | Buckwheat beverage key bioactives bioavailability and metabolism. | Plasma concentration of key bioactives (inositols and fagomines) | five hours | |
Secondary | Urine ratio of myo and D-chiro inositol | Urine ratio of myo and D-chiro inositol after the consumption of a buckwheat beverage. | 0, 3 and 5 hours | |
Secondary | Urine glucose concentration | Glucose concentration in urine after the consumption of a buckwheat beverage. | 0, 3 and 5 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |